Clinical Trials on Stage III Chronic Lymphocytic Leukemia in France

Total 776 results

Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Not yet recruiting

Assessment of the Effect of Restriction on Alimentary AGE in Progression of Chronic Kidney Disease (CKD AGE)

Kidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)

France
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Hybrigenics Corporation

Unknown

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study (ICT10)

CML, Chronic Phase

France
Hospices Civils de Lyon

Unknown

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditions

United States, Canada, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

Stage III Vulvar Cancer AJCC v7 | Stage IIIA Vulvar Cancer AJCC v7 | Stage IIIB Vulvar Cancer AJCC v7 | Stage IIIC Vulvar Cancer AJCC v7 | Vulvar Squamous Cell Carcinoma | Stage IVA Vulvar Cancer AJCC v7

United States
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
University Hospital, Angers

Active, not recruiting

Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality (PALERMO)

Chronic Myeloid Leukemia (CML)

France
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Withdrawn

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

Leukemia

United States
Centre Hospitalier Henri Duffaut - Avignon

Recruiting

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia (IPA-LMC)

Chronic Myelogenous Leukemia - Chronic Phase

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
Centre Hospitalier Universitaire de Nīmes

Withdrawn

Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms (abl LMC)

Leukemia, Myeloid, Chronic-Phase

France
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Centre Hospitalier Universitaire de Besancon

Completed

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor (PAMIR01)

Chronic Leukemia

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
University Hospital, Angers

Completed

Vascular Dysfunction and Antiangiogenic Therapy (DYVA-AAGG)

Solid Tumor | Endothelial Dysfunction | Tumor Angiogenesis | CML (Chronic Myelogenous Leukemia)

France
Centre Hospitalier Universitaire de Besancon

Completed

Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (CAR-LMC)

Chronic Myeloid Leukemia

France
Centre Hospitalier Universitaire de Saint Etienne
Institut de Cancérologie de la Loire

Recruiting

Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (PHARM-LMC)

Chronic Myeloid Leukemia

France
GERCOR - Multidisciplinary Oncology Cooperative...
HalioDx; Methodology and quality of life unit in oncology, University hospital...

Unknown

Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment

Colorectal Cancer | Stage III Colon Cancer

France
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Centre Hospitalier Universitaire de Nice

Unknown

Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia

France
Jules Bordet Institute

Active, not recruiting

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (REGINA)

Rectal Cancer Stage II | Rectal Cancer Stage III

Belgium, France
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Institut de Cancérologie de Lorraine

Completed

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer (TRIDICOL)

Cervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical Cancer

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
Nurix Therapeutics, Inc.

Active, not recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM)

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
University of California, Irvine

Recruiting

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia

United States
BioNTech SE
Genentech, Inc.

Recruiting

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, United Kingdom, Germany, Belgium, Sweden
Hospices Civils de Lyon
Novartis

Unknown

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PETALs)

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
National Cancer Institute (NCI)

Suspended

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma

United States
Novartis Pharmaceuticals

Completed

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis; Ministry of Health, France

Terminated

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Chronic Myeloid Leukemia

France
Bristol-Myers Squibb

Completed

A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Chronic Myeloid Leukemia

France
University Hospital, Bordeaux
Bordeaux PharmacoEpi

Completed

Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach (ECOSTIM)

Hematologic Diseases | Chronic Myeloid Leukemia

France
Poitiers University Hospital
Novartis; Roche Pharma AG; Ministry of Health, France

Completed

STI571 ProspectIve RandomIzed Trial: SPIRIT (SPIRIT)

Chronic Myeloid Leukemia

France
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University Hospital, Bordeaux

Recruiting

CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid)

Chronic Myeloid Leukemia

France
European Organisation for Research and Treatment...
Pfizer; ETOP IBCSG Partners Foundation; UNICANCER; Breast International Group; SOLTI... and other collaborators

Active, not recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Breast Cancer Stage II | Breast Cancer Stage III

Spain, France, Italy, Belgium, Jordan, Poland, Germany, United Kingdom, Portugal
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Intraductal Papillary Mucinous Neoplasm of the Pancreas

United States

Clinical Trials on Stage III Chronic Lymphocytic Leukemia in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations